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among children and adolescents.METHODS: The primary data source is the Mar-
ketScanMedicaid database from 2002 to 2007. A total of 783,368 patients (ages 0-18)
with asthma were selected and divided into two cohorts: 405,941 with newly-diag-
nosed asthma and 377,427 with pre-existing asthma. Drug use was tracked of
inhaled corticosteroids (ICSs), LABAs, ICS/LABA combination drugs, short-acting
beta agonists (SABAs), leukotriene modifiers, and oral and IV steroids. Cox propor-
tional hazard regressionswere estimated to assess the risk of SAEs associatedwith
different drug regimens. RESULTS: Approximately 9.5% patients were hospitalized
or received intubation, while 60.8% visited the emergency department (ED). Hazard
ratios of ED visits for newly-diagnosed and pre-existing-asthma patients were as
follows: 0.60 (0.53-0.69) and 0.68 (0.62-0.75) for patients on a LABAwithout ICS; 0.69
(0.67-0.72) and 0.77 (0.75-0.80) for those on a LABA/ICS single inhaler; and 1.43
(1.41-1.45) and 1.33 (1.31-1.34) for AfricanAmericans, respectively. Hazard ratios for
hospitalization or intubation for newly-diagnosed and pre-existing-asthma pa-
tients were as follows: 0.43 (95% CI 0.22-0.84) and 1.30 (0.96-1.76) for patients on a
LABAwithout ICS; 1.19 (1.05-1.36) and 1.65 (1.45-1.89) for those on a LABA/ICS single
inhaler. Other key risk factors (p0.0001) included an alcohol/substance abuse
disorder, pregnancy, obesity, and upper respiratory tract infection.CONCLUSIONS:
Relative to SABA-only therapy, LABA use is associatedwith a lower risk of ED visits.
Certain patients with asthma, such as pregnant adolescents and African Ameri-
cans, are particularly vulnerable to SAEs.
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OBJECTIVES: The purpose of this study is to determine whether there is an in-
creased prevalence of OLD in patients with obstructive sleep apnea (OSA).
METHODS: The prevalences of COPD, asthma, and COPD combined with asthma
(ICD-9 coding) were compared between 1497 adult OSA patients and a 1489 control
patients, matched for age, gender, geographic location, and primary care physi-
cian. Co-morbidity burden was assessed using the Charlson Co-morbidity Index
(CCI). The prevalences of specific co-morbidities were measured in the OLD groups
between patients with OSA and the matched control group. RESULTS: COPD,
asthma and COPD combined with asthmawere found to bemore prevalent among
OSA patients compared to thematched controls. Prevalences among patients with
andwithout OSA respectivelywere: COPD: 7.6%, 3.7%(P .0001); asthma: 10.4%, 5.1
% (P  .0001), COPD plus asthma: 3.3%, 0.9% (p  .0001). CCI was greater for OSA
patients (2.3  0.2) than for controls (1.9  1.8; p  .0001). These trends held for all
severity ranges of OSA. For patients with COPD, OSA was associated with greater
prevalence of diabetes (50.9% vs. 22%, p0.004) and obesity (78.9% vs. 31.7%, p 
0.0001). Patients with OSA and COPDwere characterized bymore severe hypoxia at
night compared with the OSA patients without OLD. CONCLUSIONS: OSA was
associatedwith increased prevalence of OLDs. This was true for COPD, asthma and
patients with both diagnoses. Further, increased prevalence rates of OLD were
found in all ranges of OSA severity.
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BACKGROUND: Omalizumab is licensed as an add-on therapy for the treatment of
uncontrolled severe allergic asthma. It was granted reimbursement by the French
National Health Pricing Authority – The Economic Committee on Health Care Prod-
ucts (CEPS), under the provision that the manufacturer committed to conducting
an independent comparative-effectiveness study to demonstrate improved out-
comes for patients taking omalizumab in real-life settings. OBJECTIVES: To assess
whether the use of omalizumab as an add-on therapy for uncontrolled severe
asthma was associated with a decreased risk of hospitalization and emergency
room visits (HERV) due to asthma exacerbations.METHODS:A ‘before-after cohort’
methodologywas used to assess the relative effectiveness of omalizumab. A cohort
of adult patients with uncontrolled severe asthma, free of omalizumab at entry,
was recruited from 163 pulmonary medicine centers and observed naturalistically
over 2 years, before-after the introduction and use of omalizumab. The relative rate
of HERV was assessed using a Cox time-varying regression model with Prentice–
Williams-Gill correction for auto-correlated data (SAS-GENMOD). Results were ad-
justed using propensity scores for all potential confounders including the history of
hospitalization, corticosteroid use, smoking history, allergy history and others.
RESULTS:The cohort recruited 767 patients, ofwhom374 took omalizumab at least
once. Omalizumabusewas associatedwith an adjusted relative risk of HERVof 0.56
(95% CI: 0.43-0.74) when compared to non-use as a whole and 0.40 (95% CI: 0.28-
0.58) when only omalizumab users are considered before-after introduction of the
drug.CONCLUSIONS:A before-after cohortmethodology ensured a successful cov-
eragewith evidence development of a new drug in the treatment of severe asthma.
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OBJECTIVES: This review aims to identify risk factors for mortality among patients
with chronic obstructive pulmonary disease (COPD). METHODS: We searched
PubMeddatabase using the terms: “pulmonary disease, chronic obstructive”, “mor-
tality”, “risk factors” and “predictor”. We included only studies among patients
with a primary diagnosis of COPD and excluded non-English publications, litera-
ture reviews or editorials. RESULTS: We initially identified 335 articles, among
which 60 articles met inclusion criteria. We found seven additional studies from
the references. Key risk factors formortality (# significant vs non-sigificant studies)
were: 1) Forced expiratory volume per second (FEV1) (14 vs 19), dyspnea (3 vs 4),
partial arterial carbon dioxide tension (5 vs 12), and partial pressure of oxygen (5
vs13); 2)Charlson comorbidity index (7 vs 8); 4) disease severity index: Global ini-
tiative for Obstructive LungDisease stage (3 vs 2) andAcute Physiology andChronic
Health Education II score (3 vs 1); 5) quality of life (QoL): St George’s Respiratory
Questionnaire score(6 vs 2); 6)malnutrition: Bodymass index (BMI) (7 vs 22) and Fat
free mass index (2 vs 2); 7) previous hospitalization (10 vs 5); 8) inflammatory
marker (7 vs 3); 9) Age (26 vs 18) and smoking (5 vs 8). Only 9 studies implemented
a multidimensional risk indexes (MRIs) such as the BODE (BMI, Obstructive, Dys-
pnea, and Exercise Capacity) index, REFI (Respiratory Functional Impairment) in-
dex and PILE (FEV1%, interleukin-6, and knee extensor strength) score, and all
studies found that MRIs were predictive of mortality HADO score and PILE score,
which displayed more strength and advantage in predicting mortality than using
the single factor as no study was found where use of an MRI was not predictive.
CONCLUSIONS: Age, QoL, previous hospitalization, comorbidities, and inflamma-
tory markers were more consistently found to be risk factors. Multidimensional
risk scores should be used to assess mortality risk when possible.
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OBJECTIVES: Tobacco use remains the leading preventable cause of premature
death worldwide. In the Middle East, tobacco use continues to increase with re-
ported smoking rates ranging from 40-60%. The objectives were to determine the
rate of cigarette smoking among a sample of adults in Jordan, a small Middle
Eastern country, and correlates of its use. METHODS: A cross-sectional survey
designwas conducted in a convenience sample of adults inAmman, Jordan. Survey
questions included socio-demographic characteristics, current and history of to-
bacco smoking, environmental and behavioral determinants of smoking. Three
multivariate logistic regression models were constructed to determine predictors
of cigarette use with the following outcomes: past 30-day use vs. no use (model 1),
past 7-day use vs. no use (model 2), and past 24-hour use vs. no use (model 3). All
analyses were carried out using SAS 9.2. RESULTS: A total of 600 participants com-
pleted survey. Approximately half of the samplewas female (51.56%) and themean
age was 27 years. Past 30-day cigarette use was reported in 45% of the population,
while 41% reported smoking a cigarette in the past 7 days, andmore than one third
(36%) in the past 24 hours. Male gender (OR 4.475model 1, OR 7.456model 2, OR
20.578 model 3), age older than 25 (OR  2.952 model 1, OR  5.256 model 2, OR 
8.165 model 3), lower education level (OR  7.128 model 1, OR  9.766 model 2,
OR 8.265model 3), and past cigar use (OR 3.405model 1, OR 4.339model 2, OR
 2.669model 3) were significant predictors of cigarette smoking. Participants who
were satisfied with their health were less likely to be smokers (OR 0.231 model 2,
OR 0.243model 3).CONCLUSIONS: The findings underscore themagnitude of the
smoking problem in the general population in Jordan and the urgent need for
effective prevention and intervention strategies. Future research should focus on
developing intervention strategies that incorporate the predictors identified above.
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OBJECTIVES:Waterpipe smoking is a new trend in tobacco use with a growing pop-
ularity and unsubstantiated belief that the practice is safe. The objectives were to
determine the rate of waterpipe smoking among a sample of adults in Jordan and
correlates of its use.METHODS: A cross-sectional survey was administered in a con-
venient sample of adults in Amman, Jordan (n  600). Survey included socio-demo-
graphic characteristics, current and history of tobacco smoking, environmental and
behavioral smoking determinants like peer influence, and perceived harm. Three
multivariate logistic regression models were constructed to determine predictors of
waterpipeuse for the followingoutcomes: previous lifetimeuseofwaterpipe to smoke
tobacco vs. no use (model 1), previous 30-day use vs. no use (model 2), and previous
7-day use versus nouse (model 3). Resultswere presented as adjusted odds ratios (OR)
with 95% confidence intervals (CI). All analyses were carried out using SAS statistical
package version 9.2.RESULTS: The sample consisted of 51.56% femalewithmean age
of 27 years. More than half of the sample (53%) had previously smoked tobacco using
a waterpipe, a third during the past month (33.94%), and 22% during the past week.
Previous cigarette use (OR  6.37 model 1, OR  3.38 model 2, OR  4.29 model 3),
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previous cigar use (OR 3.44model 1, OR 2.05model 2, OR 2.67model 3), previous
alcohol use (OR 2.1 model 1), having friends (OR 3.87model 1, OR 2.74model 2)
and/or siblings (OR  3.18 model 1, OR  2.53 model 2, OR  2.86 model 3) that use
waterpipes, were significant predictors of waterpipe smoking. Perception of harm
equivalent to cigarettes ormorewas associatedwith less use (OROR 0.262model
2, OR  0.305 model 3). CONCLUSIONS: High rates of waterpipe smoking in both
gendersweredocumented, evenamongparticipants recognizing theassociatedharm.
Data suggests the importance of incorporating the predictors identified in future in-
tervention strategies.
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OBJECTIVES: To assess the association between use of inhaled tobramycin andmor-
tality in patientswith cystic fibrosis and chronic Pseudomonas aeruginosa (PA) infection.
METHODS: Patients aged 6 years with FEV1 %-predicted 25-75% and chronic PA
infection were identified from the United States Cystic Fibrosis Foundation’s Patient
Registry (1996 –2008). Patients were followed from the first year in which all these
criteria weremet (index year) to death or end of continuous data availability. Longitu-
dinal logistic regression was used to assess the association between current-year re-
porteduseof inhaled tobramycin and subsequent-yearmortality,with adjustment for
demographics, comorbidities, reported use of dornase alpha or high-dose ibuprofen,
FEV1 %-predicted and medical resource use. RESULTS: Among 12,740 patients meet-
ing inclusion criteria, 2,538 deaths were observed during a median follow-up of 6
years. At index, mean age was 22 years, mean FEV1 %-predicted was 62%, 16% were
underweight for age and 64% reported inhaled tobramycin use. After regression ad-
justment, use of tobramycin inhalation solutionwas associatedwith a significant 21%
reduction in the odds of subsequent yearmortality (odds ratio: 0.79, P 0.001). Use of
dornase alfa was similarly associated with reduced mortality (odds ratio: 0.85, P 
0.005). In the same regression model, underweight for age, cystic fibrosis-related dia-
betes, female gender,worse lung function and cultures positive for PAor Burkholderia
cepacia complex, amongmultiple other patient characteristics, were associated with
significantly increased mortality. Adjusted mortality rates for patients reporting to-
bramycin inhalationsolutionuse inall vs.noneof the follow-upyearswere1.3vs. 2.1%
at 2 years, 5.2 vs. 8.0% at 5 years and 9.9 vs. 15.0% at 10 years. CONCLUSIONS: After
adjusting for clinical status and other treatments, inhaled tobramycin use was asso-
ciated with significantly reduced mortality among cystic fibrosis patients meeting
recommended criteria for inhaled tobramycin use.
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OBJECTIVES: Cystic fibrosis (CF) is the most common fatal genetic disease in Cau-
casians with an annual birth incidence of 1:2,500. CF is ultimately fatal due to
progressive dysfunction of organs such as lung and pancreas. Improved knowledge
of the ion channel defect that causes the disease has raised the possibility of
treating the cause of CF. To develop an understanding of how different factors
contribute to disease progression, published evidencewas used to develop amodel
of mortality as a function of age and prognostic factors. METHODS: A systematic
literature review of CF disease progression was performed in Medline and Embase.
Prospective and retrospective cohort studies as well as case-control studies were
included if they reported mortality jointly with prognostic factors. Covariates of
interest included gender, lung function, weight-for-age, pancreatic sufficiency, di-
abetes, lung microflora and number of acute exacerbations. Results were synthe-
sized by means of Bayesian meta-analysis techniques. RESULTS: Seven studies
provided data on over 22,000 patients, which helped to develop a survival model
based on age and the prognostic factors. Survival over time was described with a
Gompertz model with its scale parameter affected by birth cohort, gender, lung
function, infection with Burkholderia cepacia and Staphylococcus aureus, diabetes,
number of exacerbations, and pancreatic sufficiency. The shape parameter was
assumed to be only affected by birth cohort. CONCLUSIONS: A survival model was
developed that estimates remaining life expectancy for CF patients based on their
clinical characteristics. Lung function is the primary determinant of life expec-
tancy, but several other factors have major impact. Of these, lung function and
acute exacerbations are direct targets of intervention, while infections may be
prevented or treated, and diabetes and pancreatic insufficiency may be methodi-
cally managed to potentially improve survivorship.
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OBJECTIVES: The purpose of the study is to compare the costs, cost drivers and
prevalence of COPD-related hospitalizations for Hispanic andWhite patients in US
hospitals. METHODS: A retrospective cohort of COPD related hospitalized patient
discharges in 2007 were identified from a nationally representative database of
over 500 hospitals. Subjects were included if they had primary diagnosis code for
COPD (ICD9-CM 491, 492 or 496), Hispanic or White race and of age 18. COPD
related discharge rates for US population were calculated using hospital discharge
data and projection weight methodology and were further stratified by race. His-
panic discharges were matched (1:3) to comparison group of White discharges by
sex, severity score, and 5-year age ranges for an analysis of mortality and mean
costs. Unadjustedmortality andmean costs were compared by race, and cost driv-
ers were identified using a gamma generalized linear model incorporating gener-
alized estimating equations to account for the non-independent matched
discharges. RESULTS: The calculated national estimates for COPD related dis-
charges were: 490,636 total discharges including 71.4%White and 2.6% (n 12,661)
Hispanic. The study population was comprised of a cohort of 1,644 Hispanic dis-
charges meeting the inclusion criteria and a matched group of 4,932 White dis-
charges. For matched discharges the mortality rate for Whites was significantly
higher than Hispanics (1.4% White vs. 0.23% Hispanic, p.006). Hispanics had sig-
nificantly higher (P.01) unadjustedmean total patient costs ($7,356) versuswhites
($6,748), with no difference in length of stay. Hispanic hospitalizations had signif-
icantly higher costs than White hospitalizations (P  .0001). Regression analysis
identified the significant cost drivers: severity score, Hispanic race, LOS, ICU days,
urban hospital, and teaching hospital, (all with P  .025). CONCLUSIONS: As the
Hispanic population and COPD prevalence continue to rise; differences in burden,
cost, cost-drivers and treatment patterns in Hispanics warrant additional investi-
gation in an attempt to target services and reduce the burden.
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OBJECTIVES: In Nicaragua, 30% of current morbidities are associated with tobacco
smoking. Tobacco control policy measures have been initiated in this Central Ameri-
can country, however thepopulationdoesn’t have full consciousness of the long-term
consequences of tobaccouse. The aimof this studywas to compare thedirectmedical
costs of smoking cessation therapies with varenicline, nicotine replacement therapy
(NRT) and unaided cessation in Nicaragua over two time-horizons: 10 and 20 years.
METHODS: The current annual costs of chronic obstructive pulmonary disease
(COPD), lungcancer, coronaryheartdisease (CHD)andstrokewereestimatedbasedon
the current annual incidence for each disease using one public hospital databases
(Hospital Lenin Fonseca, 2010). The Benefits of Smoking Cessation on Outcomes (BE-
NESCO) simulationmodel was used to obtain the projected direct costs for each strat-
egy. An adult cohort (n3,639,948) fromNicaraguawas used and the assessment was
conducted using the healthcare payer’s perspective. Costs were discounted at 3% an-
nually. Probabilistic sensitivity analyses were conducted using Monte Carlo second
order approach. RESULTS: Varenicline is associatedwith the highest healthcare cost-
savings compared with the other two alternatives at 10 and 20 years. Results at 10
years, showed that varenicline would save US$126,599 and US$188,582 against NRT
and unaided cessation, respectively. In 20 years, savings would be US$3,609,463 and
US$5,971,233 against NRT and unaided cessation. The results of probabilistic sensitiv-
ity analyses support these findings. CONCLUSIONS: The use of a smoking cessation
therapy with varenicline would generate savings in the long-term in almost 6million
dollars to Nicaragua’s healthcare institutions.
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OBJECTIVES: To estimate the direct medical costs and indirect costs of food-in-
duced allergic reactions and anaphylaxis in the U.S. METHODS: Costs were esti-
mated with a bottom-up approach from a societal perspective: the average cost of
illness per patientwas calculated andmultiplied by reported prevalence estimates.
Patients with an inpatient admission, emergency department admission, office-
based physician visit, or outpatient visit for a food-induced allergic reaction were
identified from a list of federally administered 2006 and 2007 databases by using
ICD-9 codes. Indirect costs were quantified by estimating the lost productivity, in
terms of lost earnings due to absenteeism and mortality, of patients or caregivers.
Sensitivity analyses were conducted to measure the robustness of the estimates.
RESULTS: For 2007, direct medical costs were $225 million and indirect costs were
$115million. Office visits accounted for 52.5% of costs, and the remainder was split
between emergency visits (20%), inpatient hospitalizations (11.8%), outpatient vis-
its (3.9%), ambulance runs (3%), and epinephrine devices (8.7%). Simulations from
probabilistic sensitivity analyses suggested mean direct medical costs were $307
million and indirect costswere $203million.CONCLUSIONS:The economic burden
of allergic reactions due to food and anaphylaxis was an estimated half a billion
dollars in 2007. Ambulatory visits accounted for more than one half of costs.
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